

**BIOGRAPHICAL SKETCH**

NAME Glidden, David V.		POSITION TITLE Professor of Biostatistics	
eRA COMMONS USER NAME (credential, e.g., agency login) glidden			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of California, Berkeley, CA	B.A.	1988	Statistics
University of Washington, Seattle, WA	Ph.D.	1993	Biostatistics
Harvard University, Boston, MA	Fellowship	1995	Biostatistics

**A. Positions**

1988 – 1993	University of Washington	Research Assistant
1993 – 1995	Harvard University	Research Fellow
1995 – 1997	Harvard University	Research Associate
1997 – 2003	University of California, San Francisco	Assistant Adjunct Professor
2003 – 2007	University of California, San Francisco	Associate Professor in Residence
2007 –	University of California, San Francisco	Professor in Residence

**Honors and Awards**

1988	W.W. Stout Fellowship, Graduate School, University of Washington
1988 – 1990	Graduate Fellowship Award, Graduate School, University of Washington
1990 – 1993	National Research Service Award, National Heart, Lung and Blood Institute
1993	School of Public Health Outstanding Student Citation for Biostatistics, Univ. of Washington
2007	TICR Award for Excellence in Teaching

**B. Selected from over 60 peer-reviewed publications.**

- Lafferty WE, Glidden D, Hopkins SG. Survival trends of people with AIDS in Washington State. *American Journal of Public Health* 81:217-219, 1991.
- Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials with potential applications in cancer and AIDS research. *Statistics in Medicine* 13:955-968, 1994.
- Wei LJ, Glidden DV. An overview of statistical methods for multiple events data. *Stat Med* 16:833-9, 1997.
- Glidden DV. Checking the adequacy of the gamma frailty model for multivariate failure times. *Biometrika* 86:381-393, 1999.
- Glidden DV, Self SG. Semiparametric likelihood estimation in the Clayton-Oakes model. *Scandinavian Journal of Statistics* 26:363-372, 1999.
- Glidden DV, Wei LJ. Rank estimation of treatment differences based on repeated measurements subject to dependent censoring. *Journal of the American Statistical Association* 94:888-895, 1999.
- Staprans S, Marlowe N, Glidden D, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. *AIDS* 13:1051-1061, 1999.
- Glidden, DV. A two-stage estimator of the dependence parameter in the Clayton-Oakes model. *Lifetime Data Analysis* 6:141-156, 2000.
- Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L, Risler LJ, Bostrom B, Cowan M. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. *Bone Marrow Transplantation* 25:925-930, 2000.
- Para MF, Glidden DV, Coombs RW, et al and AIDS Clinical Trials Group Protocol 333 Team. Baseline human immuno- deficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gelcapsule saquinavir in AIDS Clinical Trials Group Protocol 333. *J Infect Dis* 182:733-743, 2000.
- Kanaya AM, Glidden DV, Chambers HF. Identifying pulmonary tuberculosis in patients with negative sputum smear results. *Chest* 120:349-355, 2001.
- Matthay KK, Panina C, Huberty J, Price D, Glidden DV, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with I-131-MIBG. *J Nucl Med* 42:1713-1721, 2001.

13. Glidden D, Kim S, Lagakos S. On the effectiveness of Remune. *Clin Diagn Lab Immunol* 8:468-9, 2001.
14. Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. *Pediatric Nephrology* 17: 1-5, 2002.
15. Glidden DV. Robust inference for event probabilities with non-Markov data. *Biometrics* 58:361-368, 2002.
16. Ladabaum U, Glidden D. Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans. *Neurogastroenterology and Motility* 14:1-7, 2002.
17. Miller SP, Weiss J, Barnwell A, Ferriero DM, Latal Hajnal B, Ferrer Rogers A, Newton N, Partridge JC, Glidden DV, Vigneron DB, Barkovich, AJ. Seizure associated brain injury in term newborns with perinatal asphyxia. *Neurology* 58:542-548, 2002.
18. Miller SP, Newton N, Ferriero DM, Partridge JC, Glidden DV, et al. MRS predictors of 30 month outcome following perinatal depression: role of socioeconomic factors. *Pediatric Research* 52:71-77, 2002.
19. Mathews CA, Glidden D, Hargreaves W. Race and psychiatric diagnoses: the effect of ethnically focused psychiatric units. *Psychiatric Services* 53:823-829, 2002.
20. Mathews CA, Glidden D, Murray S, Forster P, Hargreaves W. Matching inpatients to ethnically focused psychiatric units: effect on treatment outcome. *Psychiatric Services* 53:830-835, 2002.
21. von Scheven E, Glidden D, Elder ME. Anti  $\beta_2$ -glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. *Arthritis Care and Research* 47:414-420, 2002.
22. Ladabaum U, Fendrick AM, Glidden D, Scheiman JM. Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States. *American Journal of Gastroenterology* 97:3007-3014, 2002.
23. Glidden DV. Rejoinder to the discussion of P.R. Burton and M.P. Epstein. *Gen Epidemiol* 23:219-20, 2002.
24. Glidden DV, Liang K-Y, Chiu Y-F, Pulver AE. Multipoint affected sibpair linkage methods for localizing susceptibility genes for complex diseases. *Genetic Epidemiology* 24:107-177, 2003.
25. Fine JP, Glidden DV, Lee KE. Simple estimator for shared frailty model. *Journal of the Royal Statistical Society, Series B* 65:317-329, 2003.
26. Keller RL, Glidden DV, Paek BW, Goldstein RB, Feldstein VA, Callen PW, Filly RA, Albanese CT. The lung-to-head ratio and fetoscopic temporary tracheal occlusion: prediction of survival in severe left congenital diaphragmatic hernia. *Ultrasound in Obstetrics Gynecology* 21:244-9, 2003.
27. Flori HR, Ware LB, Glidden D, Matthay MA. Early elevation of plasma soluble intercellular adhesion molecule-1 in pediatric acute lung injury identifies patients at increased risk of death and prolonged mechanical ventilation. *Pediatric Critical Care Medicine* 4:315-321, 2003.
28. Kaufman SA, Miller SP, Ferriero DM, Glidden DV, Barkovich AJ, Meeks L, Partridge JC. Encephalopathy as a predictor of MRI abnormalities in asphyxiated newborns. *Pediatric Neurology* 5:342-6, 2003.
29. Glidden DV, Vittinghoff E. Modelling clustered survival data from multicentre clinical trials. *Stat Med* 23:369-88, 2004.
30. Miller SP, Latal B, Clark H, Barnwell A, Glidden D, Barkovich AJ, Ferriero DM, Partridge JC. Clinical signs predict 30-Month neurodevelopmental outcome following neonatal encephalopathy. *Am J Obstet Gynecol* 190:93-9, 2004
31. O'Hare AM, Glidden DV, Fox CS, Hsu C-Y. High Prevalence of peripheral arterial disease in persons with renal insufficiency: results from NHANES 1999-2000. *Circulation* 109:320-3, 2004.
32. DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. *J Clinical Oncology* 22:2452-60, 2004.
33. Miller SP, McQuillen PS, Vigneron DB, Glidden DV, et al. Preoperative brain injury in newborns with transposition of the great arteries. *Ann Thorac Surg* 77:1698-706, 2004.
34. Mathews CA, Waller J, Glidden D, et al. Self-injurious behavior in Tourette syndrome: correlates to compulsivity and impulse control. *Journal of Neurology, Neurosurgery & Psychiatry* 75:1149-55, 2004.
35. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression Methods in Biostatistics: Linear, Logistic, Survival and Repeated Measures Models. Springer, New York, 2005.
36. Flori HR, Glidden DV, Rutherford GW, Matthay MA. Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality. *Am J Respiratory and Critical Care Medicine* 171:995-1001, 2005.
37. Miller SP, Ramaswamy V, Michelson D, Barkovich AJ, Holshouser B, Wycliffe N, Glidden DV, et al. Patterns of brain injury in term neonatal encephalopathy. *Journal of Pediatrics* 146:453-460, 2005.
38. Hopkins LM, Caughey AB, Glidden DV, Laros RK Jr. Racial/ethnic differences in perineal, vaginal and cervical lacerations. *American Journal of Obstetrics and Gynecology* 193:455-459, 2005.

39. Miller SP, Ferriero DM, Leonard C, Piecuch R, Glidden DV, Partridge JC, Perez M, Mukherjee P, Vigneron DB, Barkovich AJ. Early brain injury in premature newborns detected with magnetic resonance imaging is associated with adverse early neurodevelopmental outcome. *Journal of Pediatrics* 147:609-616, 2005.
40. Peretz D, Supattapone S, Giles K, Vergara J, Freyman Y, Lessard P, Safar JG, Glidden DV, McCulloch C, Nguyen HO, Scott M, Dearmond SJ, Prusiner SB. Inactivation of prions by acidic sodium dodecyl sulfate. *Journal of Virology* 80:322-331, 2006.
41. McQuillen PS, Hamrick SE, Perez MJ, Barkovich AJ, Glidden DV, Karl TR, Teitel D, Miller SP. Balloon atrial septostomy is associated with preoperative stroke in neonates with transposition of the great arteries. *Circulation* 113:280-285, 2006.
42. Miller SP, Mayer EE, Clyman RI, Glidden DV, Hamrick SE, Barkovich AJ. Prolonged indomethacin exposure is associated with decreased white matter injury detected with magnetic resonance imaging in premature newborns at 24 to 28 weeks' gestation at birth. *Pediatrics* 117:1626-31, 2006.
43. Nuckton TJ, Glidden DV, Browner WS, Claman DM. Physical examination: Mallampati score as an independent predictor of obstructive sleep apnea. *Sleep* 29:903-8, 2006.
44. Miller SP, Wu YW, Lee J, Lammer EJ, Iovannisci DM, Glidden DV, Bonifacio SL, Collins A, Shaw GM, Barkovich AJ, Ferriero DM. Candidate gene polymorphisms do not differ between newborns with stroke and normal controls. *Stroke* 37(11):2678-83, 2006.
45. Raz DJ, Glidden DV, Odisho AY, Jablons DM. Clinical characteristics and survival of patients with surgically resected, incidentally detected lung cancer. *Journal of Thoracic Oncology* 2(2):125-30, 2007.
46. McQuillen PS, Nishimoto MS, Bottrell CL, Fineman LD, Hamrick SE, Glidden DV, Azakie A, Adatia I, Miller SP. Regional and central venous oxygen saturation monitoring following pediatric cardiac surgery: concordance and association with clinical variables. *Pediatric Critical Care Medicine* 8(2):154-160, 2007.
47. McQuillen PS, Barkovich AJ, Hamrick SE, Perez M, Ward P, Glidden DV, Azakie A, Karl T, Miller SP. Temporal and anatomic risk profile of brain injury with neonatal repair of congenital heart defects. *Stroke* 38:736-41, 2007.
48. Glidden DV. Pairwise dependence diagnostics for clustered failure time data. *Biometrika* 94:371-85, 2007.
49. Miller SP, McQuillen PS, Hamrick S, Xu D, Glidden D, Karl T, Azakie A, Ferriero DM, Barkovich AJ, Vigneron DB. Abnormal brain development in newborns with congenital heart disease. *New England Journal of Medicine* 357(19):1928-38, 2007.
50. Liu KD, Glidden DV, Eisner MD, et al; National Heart, Lung, and Blood Institute ARDS Network Clinical Trials Group. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. *Critical Care Medicine* 35(12):2755-61, 2007.

### **C. Research Support.**

#### **Ongoing Research Support**

Grant / Glidden (PI) 9/1/07 – 8/31/10

Gates Foundation/Gladstone Inst.

*Chemoprophylaxis for HIV Prevention*

Statistics Core for a randomized trial of chemoprophylaxis for HIV. This award supplements U01 AI064002 (Grant), below. Role: PI of Statistics Core subcontract.

TL1 RR024129 McCune (PI) 9/30/06 – 6/30/11

NIH-NCRR

*Clinical and Translational Science Institute*

To enhance training and infrastructure to foster the translation of discoveries in basic science into practices that promote the health of our patients and our community. Role: Co-Investigator.

U01 AI069911 Yiannoutsos / Martin (PI) 8/5/06 – 7/31/11

NIH/University of Indiana

*East Africa IEDEA Regional Consortium*

To contribute and analyze data for the International Epidemiologic Databases to Evaluate AIDS (IEDEA) from the Mbarara, Uganda-based ISS and UARCO cohorts. Role: Co-investigator

R01 AI064709 Prusiner (PI) 4/1/06 – 3/31/11

NIH-NIAID

*Preventing Human Prion Diseases – Inactivation of Prions*

Employing biophysical strategies, we plan to define the mechanism of prion inactivation using prion-infected brain homogenates and prion-coated wires, which serve as a model for surface contamination. Role: Co-inv

Program Director/Principal Investigator (Last, First, Middle):

U10 EY015114 Lietman (PI) 9/30/05 – 8/31/09  
NIH/NEI  
*The Steroids for Corneal Ulcers Trial*  
To determine if immunosuppressive agents can improve outcomes in infectious corneal ulcers. Role: Co-inv  
P30 MH62246 Morin (PI) 9/24/01 – 8/31/11  
NIH/NIMH  
*Center for AIDS Prevention Studies*  
The mission of the Center for AIDS Prevention Studies (CAPS) is to conduct theoretically based HIV/AIDS prevention research that will have scientific, programmatic, and policy impact. Role: Co-investigator  
P50 NS35902 Ferriero (PI) 9/1/02 – 1/31/13  
NIH/NINDS  
*Mechanisms of Ischemic Neonatal Brain Injury*  
The goal of this grant is to continue to investigate the role of ischemia in the generation of neonatal brain injury. Role: Co-investigator  
P01 NS41997 Carlson; Project 3 Prusiner (PI) 7/1/07 – 6/30/12  
NIH-NINDS/McLaughlin Research Inst.  
*Functional Genetics of Susceptibility to Prions*  
To develop cell culture models based on neurospheres, to understand the cell biology of various prions strains, and to enable rapid assay of of prions from a range of species. Role: Co-investigator

**Completed Research Support**

U01 AI064002 Grant / Shafer (PI) 8/15/05 – 1/31/09  
NIH/NIAID/Gladstone Inst. Effort ended 1/31/08  
*Chemoprophylaxis for HIV Prevention in Peruvian Men*  
To evaluate the safety and efficacy of chemoprophylaxis for HIV prevention in a randomized and blinded trial of daily oral tenofovir versus placebo among men in Peru. Role: Co-investigator  
R01 NS046432 Barkovich (PI) 9/15/04 – 5/31/08  
NIH/NINDS Effort ended 5/31/07  
*MRSI and DTI of Brain Injury in Preterm Neonates*  
To determine if MR techniques detect metabolic or microstructural abnormalities associated with subsequent cognitive, visual, motor, and auditory deficits more accurately than current clinical parameters. Role: Co-inv  
R01 HL65411 Glidden (PI) 4/1/01 – 3/31/06  
NIH/NHLBI  
*Failure Time Methods for Family Disease Studies*  
The long-term objective of this research is the development of sound methodologies that will facilitate studying the role of both genetic and environmental factors in cardiovascular disease. The short-term goal of the proposal is to develop statistical methods for age at onset data from population-based family studies of disease incidence. Role: Principal Investigator  
U62/CCU922423 Rutherford (PI) 9/30/02 – 3/31/06  
CDC  
*Univ. Technical Assistance Projects in Support of the Global AIDS Program: Uganda*  
Project will provide technical assistant in support of the Global AIDS Program to Uganda. Assistance will be provided in the areas of training, research methodology, and evaluation and monitoring. Role: Co-investigator  
M01 RR01271 Kessler (PI) 2/1/97 – 9/30/05  
NIH/NCRR  
*Pediatric Clinical Research Center*  
The major goals of this project are to provide the infrastructure and support for the conduct of pediatric clinical investigation. Role: Co-Investigator  
U01 AI054241 Shafer (PI) 9/15/03 – 12/31/04  
NIH/NIAID  
*Phase I/II trial of Pharmacological HIV-1 Prevention*  
To evaluate the acceptability and safety of HIV-1 chemoprophylaxis in a double blind phase I/II placebo controlled randomized trial of tenofovir among HIV-1 uninfected women at risk in Cambodia. Role: Co-inv